RCM
ELVN icon

RA Capital Management’s Enliven Therapeutics ELVN Stock Holding History

RA Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-848,986
Closed -$17M – 70
2025
Q2 		$17M Hold
848,986
– – 0.29% 38
2025
Q1 		$16.7M Hold
848,986
– – 0.28% 49
2024
Q4 		$19.1M Sell
848,986
-212,247
-20% -$5.5M 0.25% 57
2024
Q3 		$27.1M Sell
1,061,233
-1,061,232
-50% -$24.6M 0.31% 50
2024
Q2 		$49.6M Hold
2,122,465
– – 0.66% 38
2024
Q1 		$37.3M Hold
2,122,465
– – 0.48% 47
2023
Q4 		$29.4M Hold
2,122,465
– – 0.46% 40
2023
Q3 		$29M Hold
2,122,465
– – 0.57% 46
2023
Q2 		$43.3M Hold
2,122,465
– – 0.82% 36
2023
Q1 		$46.5M Buy
2,122,465
+1,309,784
+161% +$26.6M 1.05% 32
2022
Q4 		$13.3M Buy
+812,681
New +$13M 0.27% 49
2021
Q3 		– Sell
-62,201
Closed -$1.97M – 99
2021
Q2 		$1.97M Hold
62,201
– – 0.03% 90
2021
Q1 		$2.1M Hold
62,201
– – 0.03% 81
2020
Q4 		$5.49M Sell
62,201
-234
-0.4% -$19.6K 0.08% 78
2020
Q3 		$5.08M Sell
62,435
-144,902
-70% -$13.1M 0.09% 66
2020
Q2 		$22.9M Sell
207,337
-156,250
-43% -$17.5M 0.45% 39
2020
Q1 		$23.3M Buy
+363,587
New +$23.2M 0.74% 34

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

RA Capital Management's ELVN Position: Q3 2025 in Review

RA Capital Management sold out of Enliven Therapeutics (ELVN) in Q3 2025, closing a stake of 848,986 shares — an estimated $17M sold.

RA Capital Management first reported a position in ELVN in Q1 2020 and held it in 17 quarters. The position peaked at $49.6M in Q2 2024. 134 funds tracked by Wall St. Rank hold ELVN as of Q3 2025.

  • RA Capital Management reported no remaining Enliven Therapeutics position as of Q3 2025 after selling out during the quarter.
  • RA Capital Management sold 848,986 Enliven Therapeutics shares in Q3 2025, an estimated $17M.
  • RA Capital Management first reported a position in Enliven Therapeutics in Q1 2020 and held it in 17 quarters.
  • RA Capital Management's Enliven Therapeutics position peaked at $49.6M in Q2 2024.
  • 134 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2025.

Based on RA Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.